Table 3.

Security outcome evaluation in Aterofisiol^® group versus placebo group

Cerebrovascular events	Group A (Cardioaspirin® + Aterofisiol®) N=103	Group B (Cardioaspirin® + placebo) N=99	P-value
Amaurosis fugax	4 (3.9%)	9 (9%)	0.038
TIA	2 (1.9%)	5 (5%)	0.025
RIND	1 (0.9%)	4 (4%)	0.048
Stroke*	1 (0.9%)	2 (2%)	0.125

Note:

^*Indicates non-fatal stroke.

Abbreviations: RIND, reversible ischemic neurological disease; TIA, transient ischemic attack.